Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Three investigational obesity drugs are rewriting what's possible for weight loss in people with type 2 diabetes. Phase 3 data show retatrutide achieving over 20% weight loss, while the eloralintide-tirzepatide combo hit 23.3% — levels previously seen only with metabolic surgery. Tolerability, especially GI side effects, remains the key hurdle across all agents.
Three investigational obesity therapies presented at the EASD 2026 Annual Meeting are pushing the boundaries of pharmacologic weight loss in adults with type 2 diabetes (T2D) — a population that historically loses less weight than those without diabetes on the same treatments.
Survodutide (glucagon/GLP-1 dual agonist, SYNCHRONIZE-2): In 752 adults with T2D and obesity, the 6 mg weekly dose achieved 13.1% mean weight loss at 76 weeks (efficacy estimand) vs. 3.1% with placebo, with 64.5% of patients losing ≥5% body weight. A1c dropped by ~0.8–0.9 percentage points. However, GI adverse events were common (up to 77.7%), and ~26% of participants discontinued treatment — notably higher than comparable agents like semaglutide or tirzepatide.
Retatrutide (GIP/GLP-1/glucagon triple agonist, TRIUMPH-2): Among 1,152 adults with T2D, the 12 mg dose produced 18.8% weight loss (treatment-regimen estimand) and 20.8% (efficacy estimand) at 80 weeks — the first time >20% weight loss has been achieved pharmacologically in a T2D population. A1c fell by up to 1.5 percentage points, with 72% reaching A1c ≤6.5%. Eli Lilly plans an FDA submission in early 2027.
Eloralintide + tirzepatide (amylin + GIP/GLP-1 combo, phase 2): The highest-dose combination (eloralintide 9 mg + tirzepatide 15 mg) achieved 23.3% weight loss at 48 weeks vs. 14.8% with tirzepatide alone. Up to 77% of combination-arm participants achieved normoglycemia (A1c <5.7%). Phase 3 trials are planned by end of 2026.
Why it matters: For the first time, pharmacologic therapies are matching — and in some cases exceeding — the weight loss thresholds previously only achievable through bariatric surgery in people with T2D. These results could reshape treatment algorithms for obesity-related T2D, though tolerability and real-world adherence remain critical challenges to address before widespread clinical adoption.
